Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at American Thoracic Society (ATS) Conference 2015

Actelion Pharmaceuticals Ltd / Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at American Thoracic Society (ATS) Conference 2015 . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

ALLSCHWIL, SWITZERLAND - 13 May 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi^®), will be shared during an oral presentation at the American Thoracic Society (ATS) Conference in Denver, Colorado, USA.

The oral presentation covering results from key subgroup populations will be given by Dr. Kelly Chin of the University of Texas Southwestern Medical Center, Dallas, Texas, US at 15.45 on May 17, 2015. The abstract can now be found online here.

The ATS Conference will also see the presentation of further information from the macitentan (Opsumit^®) Phase III SERAPHIN study in a poster discussion session with a poster titled 'Prognostic Indicators of Long-Term Outcome in Pulmonary Arterial Hypertension: Results from the SERAPHIN Event-Driven Morbidity/Mortality Trial' to be presented by Dr. Marion Delcroix of the University of Leuven, Leuven, Belgium from 09.30-11.30 on May 20, 2015. The abstract can now be found online here.

Additional pre-clinical data on macitentan will be presented in a poster titled 'Therapeutic Effect of Macitentan, a Novel Dual Endothelin Receptor Antagonist, on Right Ventricular Structure and Function in Pulmonary Arterial Hypertensive Rats' from 11.30-13.15 on May 17, 2015. The abstract can now be found online here.

###

Notes to Editor:

SELEXIPAG AT ATS-15

Oral presentation:
Selexipag Prolongs the Time to Morbidity/Mortality Events in Key Subgroup Populations: Results from GRIPHON, a Randomized Controlled Study in Pulmonary Arterial Hypertension.
K.M. Chin, R. Channick, A. Frey, S. Gaine, H.-A. Ghofrani, M. Hoeper, I. Lang, V. Mclaughlin, R. Preiss, G. Simonneau, O. Sitbon, M. Stefani, V. Tapson, N. Galie, L.J. Rubin.
Sunday, May 17, 2015, 15:45 - 16:00, Bellco Theatre Section 1 (Street Level), Colorado Convention Center.

MACITENTAN AT ATS-15

Poster presentations:

[Poster Board # P501] Therapeutic Effect of Macitentan, a Novel Dual Endothelin Receptor Antagonist, on Right Ventricular Structure and Function in Pulmonary Arterial Hypertensive Rats, [Publication Number: A1953]

M. Vercauteren, H. Hadana, C. Cattaneo, M. Kramberg, C. Bortolamiol, M. Rey, B. Renault, Y. Bauer, P. Steiner, M. Iglarz, E. Vezzali, E. Weber, R. Studer, D. Strasser, O. Nayler, P. Hess, M. Clozel.

Sunday, May 17, 2015, 11.30 - 13.15 Area E, Hall A-B (Upper Level), Colorado Convention Center

[Poster Board # 202] Prognostic Indicators of Long-Term Outcome in Pulmonary Arterial Hypertension: Results from the SERAPHIN Event-Driven Morbidity/Mortality Trial, [Publication Number: A5503]

M. Delcroix, R.N. Channick, N. Galie, H.A. Ghofrani, P. Jansa, S. Mehta, L. Perchenet, T. Pulido, B.K.S. Sastry, O. Sitbon, R. Souza, A. Torbicki, P. Verweij, L.J. Rubin, G. Simonneau,

Wednesday, May 20, 2015, 09.30 - 11.30, Room 401-402 (Street Level), Colorado Convention Center

ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions.  Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;